Coherus Oncology (CHRS) Other Non-Current Assets (2013 - 2026)

Coherus Oncology has disclosed Other Non-Current Assets across 14 years of filings, most recently posting $3.6 million for Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $3.6 million, down 36.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.6 million (down 36.51% YoY), and the FY2025 annual result was $4.1 million, down 94.38% from the prior year.
• Other Non-Current Assets came in at $3.6 million for Q1 2026 at Coherus Oncology, down from $4.1 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $72.2 million in Q4 2024 to a low of $3.6 million in Q1 2026.
• The 5-year median for Other Non-Current Assets is $7.8 million (2023), against an average of $11.2 million.
• Across the five-year window, Other Non-Current Assets soared 645.2% in 2024 and plunged 94.38% in 2025, its largest moves.
• Coherus Oncology's Other Non-Current Assets stood at $8.7 million in 2022, then climbed by 11.74% to $9.7 million in 2023, then jumped by 645.2% to $72.2 million in 2024, then slumped by 94.38% to $4.1 million in 2025, then retreated by 11.4% to $3.6 million in 2026.
• The last three Other Non-Current Assets figures came in at $3.6 million (Q1 2026), $4.1 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.